.jpg)
4 hours ago
1
Article content
THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
SUBSCRIBE TO UNLOCK MORE ARTICLES
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
REGISTER / SIGN IN TO UNLOCK MORE ARTICLES
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account.
- Share your thoughts and join the conversation in the comments.
- Enjoy additional articles per month.
- Get email updates from your favourite authors.
THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account
- Share your thoughts and join the conversation in the comments
- Enjoy additional articles per month
- Get email updates from your favourite authors
Sign In or Create an Account
or
Article content
Article content
– Cybin will leverage Osmind’s 800-clinic network, point-of-care software, and real-world data to support the commercial preparation for its clinical-stage pipeline –
Article content
– Osmind is a leading service provider to psychiatry practices in the U.S. focused on advancing psychiatry through technology and services to bring innovative mental health treatments to patients in need –
Article content
TORONTO — Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced a strategic partnership with Osmind, a leading service provider advancing psychiatry through technology, services, and real-world evidence to bring innovative mental health treatments to patients in need.
Article content
Article content
“Preparation for the commercialization of our clinical stage programs is a top priority, and aligning ourselves with Osmind will help us accelerate our goals,” said Doug Drysdale, Chief Executive Officer of Cybin. “Osmind’s extensive network of over 800 psychiatry clinics in the U.S., combined with our expertise, allows us to align on and prepare for the operational infrastructure needs relevant for interventional treatments. End-to-end mapping in key areas of clinic workflow and patients’ journey such as pharmacy, fulfillment, patient access and reimbursement will lay the groundwork for commercialization of our lead clinical programs: CYB003 in Phase 3 development for the adjunctive treatment of major depressive disorder, and CYB004 in a Phase 2 study for generalized anxiety disorder. We look forward to a productive collaboration that leads to meaningful progress in transforming the treatment paradigm for patients with mental health disorders.”
Article content
By signing up you consent to receive the above newsletter from Postmedia Network Inc.
Article content
With 52.9 million people in the U.S., or nearly one in five Americans1, living with a mental illness, there remains a significant unmet need in addressing the mental health crisis. Many patients do not experience relief with the standard of care, highlighting a need for innovation and improved therapeutic options.
Article content
“We are thrilled to partner with Cybin; together, we are aligning incentives across stakeholders to help patients in need,” said Jimmy Qian, President of Osmind. “By preparing real-world care settings for next-generation neuropsychiatric interventions, Osmind is reducing friction and promoting practice success for clinicians, increasing access for patients, while supporting Cybin’s market penetration and commercial launch. Osmind and Cybin share a common mission to scale cutting-edge mental health treatments to as many patients as possible. We are delighted to support Cybin’s differentiated research, development, and commercialization efforts.”
Article content
Opportunity to Address Unmet Needs in Mental Health
Article content
- Globally, it is estimated that over 300 million people suffer from major depressive disorder (MDD)2. The global market size for major depressive disorder was estimated at $5.15 billion in 2024 and is projected to rise to $11.09 billion by 2033.3
- An estimated 21 million Americans experienced at least one major depressive episode in 2021.4 About two-thirds of patients with MDD do not experience relief with initial antidepressant treatment.5
- It is estimated that 6.8 million people in the U.S. suffer from generalized anxiety disorder (“GAD”).6 Approximately 50% of patients with GAD are unresponsive to first line treatment with selective serotonin reuptake inhibitors (“SSRIs”) and serotonin-norepinephrine reuptake inhibitors (“SNRIs”).7
Article content
Article content
About Osmind
Article content
Osmind is a public benefit corporation advancing psychiatry through technology, services, and real-world evidence to bring innovative mental health treatments to patients in need. Osmind’s psychiatry-tailored software and services, used by leading psychiatry practices across the U.S., help improve patient outcomes while driving practice success. Osmind’s network of over 800 clinics comprises the country’s largest network of interventional psychiatry practices. Simultaneously, Osmind’s clinic network, point-of-care software, and real-world data support life sciences companies in developing and scaling access to cutting-edge treatments.
Article content
About Cybin
Article content
Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions.
Article content
With industry leading proof-of-concept data, Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results. The Company is currently developing CYB003, a proprietary deuterated psilocin program, in Phase 3 development for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated N, N-dimethyltryptamine program in a Phase 2 study for generalized anxiety disorder. The company also has a research pipeline of investigational, 5-HT-receptor focused compounds.
Article content
Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For Company updates and to learn more about Cybin, visit www.cybin.com or follow the team on X, LinkedIn, YouTube and Instagram.
Article content
Sources
Article content
- https://www.nimh.nih.gov/health/statistics/mental-illness
- World Health Organization. (2017). Depression and other common mental disorders: global health estimates. World Health Organization. https://iris.who.int/handle/10665/254610
- Business Research Insights. (2025, March 24). Major depressive disorder market size, share, growth, and industry analysis by type (antidepressant drugs, SSRIs, SNRIs, benzodiazepines and others), by application (hospitals, clinics and others), regional insights and forecast from 2025 to 2033. Major Depressive Disorder Market Size to Hit USD 11.09 Bn by 2033. https://www.businessresearchinsights.com/market-reports/major-depressive-disorder-market-108486
- https://www.nimh.nih.gov/health/statistics/major-depression
- Little A. (2009). Treatment-resistant depression. American family physician, 80(2), 167–172.
- https://adaa.org/understanding-anxiety/generalized-anxiety-disorder-gad
- Ansara E. D. (2020). Management of treatment-resistant generalized anxiety disorder. The mental health clinician, 10(6), 326–334. https://doi.org/10.9740/mhc.2020.11.326
English (US)